Treatment of hospital-acquired pneumonia with linezolid or vancomycin: A systematic review and meta-analysis

BMJ Open

Volumn 3, Issue 10, 2013, Pages

  Kalil, Andre C ^a   Klompas, Michael ^b   Haynatzki, Gleb ^c   Rupp, Mark E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEPATITIS; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; KIDNEY FAILURE; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; NAUSEA; PANCREATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 84886700863     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003912     Document Type: Article

References (30)

1. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
2. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993;6:428-42. (Pubitemid 23306594)
3. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867-903. (Pubitemid 34774654)
4. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the united states. JAMA 2007;298:1763-71. (Pubitemid 47598444)
5. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789-97. (Pubitemid 37433574)
6. Powers JH, Ross DB, Lin D, et al. Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses. Chest 2004;126:314-15.
7. Kalil AC, Puumala SE, Stoner J. Unresolved questions with the use of linezolid vs vancomycin for nosocomial pneumonia. Chest 2004;125:2370-1. (Pubitemid 38788219)
8. Kalil AC, Murthy MH, Hermsen ED, et al. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med 2010;38:1802-8.
9. Walkey AJ, O'Donnell MR, Wiener RS. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 2011;139:1148-55.
10. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012;64:621-9
11. Sanchez Garcia M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010;303:2260-4.
12. Kullar R, Davis SL, Levine DP, et al. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011;52:975-81.
13. Pfizer Report. New phase 4 study shows higher rates of clinical and microbiological success for zyvox versus vancomycin in MRSA nosocomial pneumonia. 2010;2013.
14. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. (Pubitemid 37088507)
15. Borenstein M, Hedges LV, Higgins JP, et al. Power analysis for meta-analysisIntroduction to meta-analysis. 1st edn. John Wiley & Sons Ltd, 2009.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. (Pubitemid 17189972)
17. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
18. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000;53:1119-29.
19. Lin DF, Zhang YY, Wu JF, et al. Linezolid for the treatment of infections caused by gram-positive pathogens in china. Int J Antimicrob Agents 2008;32:241-9.
20. Rubinstein E, Cammarata S, Oliphant T, et al. Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001;32:402-12. (Pubitemid 32173626)
21. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34:1481-90. (Pubitemid 34553708)
22. Kaplan SL, Deville JG, Yogev R, et al. Linezolid versus vancomycin for treatment of resistant gram-positive infections in children. Pediatr Infect Dis J 2003;22:677-86.
23. Wunderink RG, Cammarata SK, Oliphant TH, et al. Linezolid Nosocomial Pneumonia Study Group. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003;25:980-92. (Pubitemid 36459702)
24. Jaksic B, Martinelli G, Perez-Oteyza J, et al. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006;42:597-607. (Pubitemid 43271371)
25. Kohno S, Yamaguchi K, Aikawa N, et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 2007;60:1361-9. (Pubitemid 350168334)
26. Wunderink RG, Mendelson MH, Somero MS, et al. Early microbiologic response to linezolid versus vancomycin in ventilator-associated pneumonia (VAP) due to methicillin-resistant Staphylococcus aureus (MRSA). Chest 2008;134:1200-7.
27. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008;8:53-66. (Pubitemid 351620940)
28. Beibei L, Yun C, Mengli C, et al. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents 2010;35:3-12.
29. Piaggio G, Elbourne DR, Altman DG, et al. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006;295:1152-60. (Pubitemid 43352345)
30. ICH Expert Working Group. ICH harmonised tripartite guideline: statistical principles for clinical trials. 1998.